Davita Healthcare Partners Stock News

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its position in shares of DaVita Inc. (NYSE:DVA) by 98.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 41,424 shares of the companys stock after buying an additional 20,513 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbHs holdings in DaVita were worth $4,816,000 at the end of []

Contravisory Investment Management Inc. boosted its holdings in DaVita Inc. (NYSE:DVA) by 3.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 4,228 shares of the companys stock after purchasing an additional 123 shares during the quarter. Contravisory Investment Management Inc.s holdings in DaVita were worth $492,000 at the end of the most recent []

CAPROCK Group Inc. trimmed its position in DaVita Inc. (NYSE:DVA) by 7.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,152 shares of the companys stock after selling 162 shares during the quarter. CAPROCK Group Inc.s holdings in DaVita were worth $250,000 at the end of the most recent reporting period. Several other hedge []

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

Related Stocks: EHTH , EAR , MA , ADP , GE , SPGI , DHR , WFC , PFE , MS , DVA , SIL , FTCV , EOG ,

Related Stocks: IVV , JEPI , XLE , VIG , ESGU , MTUM , AVO , DFAX , USA , CFG , CWB , FAUG , ATVI , CNC , ALXN , CBOE , AOS , DVA ,

DaVita Inc. with ticker code (DVA) have now 9 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 164 and 111 calculating the mean target price we have 125.67. With the stocks previous close at 105.81 this now indicates there is a potential upside of 18.8%. The 50 day MA is 111.76 and the 200 moving average now moves to 121. The company has a market capitalisation of $10,849m. Visit the company website at: /> [stock_market_widget type="chart" symbol="DVA" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Maverick Capital Ltd. lessened its position in DaVita Inc. (NYSE:DVA) by 47.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,716 shares of the companys stock after selling 7,718 shares during the quarter. Maverick Capital Ltd.s holdings in DaVita were worth $1,050,000 as []

Colony Group LLC increased its stake in shares of DaVita Inc. (NYSE:DVA) by 9.0% during the second quarter, HoldingsChannel.com reports. The fund owned 6,646 shares of the companys stock after purchasing an additional 546 shares during the period. Colony Group LLCs holdings in DaVita were worth $800,000 as of its most recent SEC filing. Other []

DENVER, Nov. 4, 2021 /PRNewswire/ -- DaVita Clinical Research (DCR) will present eight research abstracts from company representatives and medical professionals during the American Society of Nephrol

TEAM, DVA, FLS, JD, and SBUX have been added to the Zacks Rank #5 (Strong Sell) List on November 3, 2021.

The stock price of DaVita Healthcare (NYSE: DVA), a medical services company providing kidney dialysis services, has seen a fall of 7% last week, while it is down 10% in a month. The company recently

DaVita's (DVA) CEO Javier Rodriguez on Q3 2021 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 6.79% and -0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?